Low dose methotrexate in the first trimester of pregnancy: Results of a French collaborative study

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2360-2365

  Lewden, Bénédicte ^a   Vial, Thierry ^a   Elefant, Elisabeth ^b   Nelva, Agnès ^c   Carlier, Patrick ^d   Descotes, Jacques ^a  

^a Centre de Pharmacovigilance   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c Institut Europeen des Genomutations   (France)

^d HÔPITAL FERNAND WIDAL   (France)

Author keywords

Methotrexate; Pregnancy; Teratogenicity

Indexed keywords

FOLIC ACID; METHOTREXATE;

ADULT; ANGIOMA; ANKYLOSING SPONDYLITIS; AORTA ARCH SYNDROME; ARTICLE; BIRTH WEIGHT; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG SURVEILLANCE PROGRAM; EYELID ANGIOMA; EYELID DISEASE; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; FRANCE; GESTATIONAL AGE; HALLUX VARUS; HUMAN; LOW DRUG DOSE; MALE; NEWBORN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATERNAL-FETAL EXCHANGE; METHOTREXATE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT;

EID: 10044253361     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Barnhart K, Coutifaris C, Esposito M. The pharmacology of methotrexate. Exp Opin Pharmacother 2001;2:409-17.
2. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 1977;15:73-80.
3. Khera KS. Teratogenicity studies with methotrexate, aminopterin, and acetylsalicylic acid in domestic cats. Teratology 1976;14:21-8.
4. Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974;9:159-64.
5. Wilson JG, Scott WJ, Ritter EJ, Fradkin R. Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology 1979;19:71-9.
6. De Sesso JM, Goeringer GC. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits. Teratology 1991;43:201-15.
7. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-3.
8. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-5.
9. Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999;60:10-2.
10. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47:533-9.
11. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999;92:551-63.
12. Diniz EM, Corradini HB, Ramos JL, Brock R. Efeitos sobre o concepto do methotrexate (amnopterina) administrado a mae. Apresentacao de caso. Rev Hosp Clin Fac Med Sao Paulo 1978;33:286-90.
13. Krahenmann F, Ostensen M, Stallmach T, Huch A, Chaoui R. In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations. Prenat Diagn 2002;22:489-90.
14. Milunsky A, Graef JW, Gaynor MF. Methotrexate induced congenital malformations. J Pediatr 1968;72:790-5.
15. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 2002;99:599-602.
16. Powell H, Ekert H. Methotrexate-induced congenital malformations. Med J Aust 1971;2:1076-7.
17. Wheeler M, O'Meara P, Stanford M. Fetal methotrexate and misoprostol exposure: the past revisited. Teratology 2002;66:73-6.
18. Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 2003;101:1104-7.
19. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
20. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000;27:1872-5.
21. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92.
22. Clementi M, Di Gianantonio E, Ornoy A. Teratology Information Services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002;5:8-12.
23. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;35:409-12.
24. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
25. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations. J Pediatr 1964;64;357-71.
26. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:195-212.
27. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Perinatal outcome in pregnancies of women with connective tissue disease and inflammatory rheumatic disease in Norway. Scand J Rheumatol 1999;28:352-6.
28. Kline J, Stein Z. Spontaneous abortion. In: Bracken MA, editor. Perinatal epidemiology. New York: Oxford University Press; 1984:23-51.
29. Goldstein DJ, Sundell KL, Debrota DJ, Offen WW. Determination of pregnancy outcome risk rates exposure to an intervention. Clin Pharmacol Ther 2001;69:7-13.
30. Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175:1645-50.
31. Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003;111:1239-43.
32. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327:368-71.
33. Mamelle N, David S, Vendittelli F, et al. La santé périnatale en 2001 et son évolution depuis 1994. Résultats du réseau sentinelle Audipog. Gynecol Obstet Fertil 2002;30 Suppl 1:6-39.